Q4 2024 Management View CEO Michael Weiss highlighted the strong full-year 2024 U.S. revenue of $310 million for BRIUMVI, exceeding initial guidance and reflecting the therapy's value in treating ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $236.00. The company ...

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $109.00. The company’s ...

Mayank Mamtani is an analyst at B. Riley Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected ...

Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $38.00. Discover outperforming stocks and ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Agenus (AGEN – Research Report) today and set a price target of $11.00. Discover outperforming stocks and invest smarter with ...

Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.

Patrick Trucchio; Analyst; H.C. Wainwright. Mayank Mamtani; Analyst; B. Riley Securities. I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations of Arrowhead.